Tumor necrosis factor as a therapeutic target of rheumatologic disease (Q37008829)

17 August 2017

1 reference

title

Tumor necrosis factor as a therapeutic target of rheumatologic disease (English)

1 reference

17 August 2017

Christoph Ackermann

1

1 reference

PubMed ID

18028004

17 August 2017

Arthur Kavanaugh

series ordinal

2

1 reference

PubMed ID

18028004

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Therapeutic Targets

17 August 2017

1 reference

17 August 2017

11

1 reference

17 August 2017

11

1 reference

17 August 2017

1369-1384

1 reference

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Serious infections associated with anticytokine therapies in the rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Economic issues with new rheumatologic therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Immunohistochemical markers for arthritis in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Immunopathology of psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Epidemiology of rheumatoid arthritis: update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Epidemiology of psoriatic arthritis in the population of the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Outcome measures in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Safety and efficacy of TNFalpha blockade in relapsing vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

New drugs for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Clinical study of hereditary disorders of connective tissues in a Chilean population: joint hypermobility syndrome and vascular Ehlers-Danlos syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Adverse reactions to biologic agents: focus on autoimmune disease therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.11.11.1369

10.1517/14728222.11.11.1369

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18028004